Kiniksa Pharmaceuticals Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $7.41 billion, with shareholders equity totaling $710.19 million.
The company employs approximately 168 people and operates in the Health Care sector, within the Biotechnology industry.
Over the past 12 months, Kiniksa Pharmaceuticals Ltd. reported $945.96 million in revenue, generating net income of $109.57 million.
Key financial metrics include a P/E ratio of 67.63, a price-to-book (P/B) ratio of 10.43, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker KNSA.